Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 20-Apr 11:00 AM ET)
Market Chameleon (Tue, 10-Mar 6:33 AM ET)
Globe Newswire (Tue, 10-Mar 7:00 AM ET)
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Globe Newswire (Tue, 3-Mar 7:00 AM ET)
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Globe Newswire (Wed, 4-Feb 7:00 AM ET)
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Tenax Therapeutics trades on the NASDAQ stock market under the symbol TENX.
As of April 21, 2026, TENX stock price declined to $13.68 with 272,456 million shares trading.
TENX has a beta of 0.11, meaning it tends to be less sensitive to market movements. TENX has a correlation of 0.00 to the broad based SPY ETF.
TENX has a market cap of $235.26 million. This is considered a Small Cap stock.
In the last 3 years, TENX traded as high as $61.20 and as low as $2.77.
The top ETF exchange traded funds that TENX belongs to (by Net Assets): VTI, VXF, DFAS, DFMC, DFAC.
TENX has outperformed the market in the last year with a return of +157.1%, while the SPY ETF gained +35.2%. However, in the most recent history, TENX shares have underperformed the stock market with its stock returning -16.7% in the last 3 month period and -8.1% for the last 2 week period, while SPY has returned +4.2% and +6.9%, respectively.
TENX support price is $13.30 and resistance is $14.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TENX shares will trade within this expected range on the day.
